Studies of influences of anticancer chemotherapeutic drugs on ligand-gated potassium current in heart muscle and their mechanism of actions

抗癌化疗药物对心肌配体门控钾电流的影响及其作用机制研究

基本信息

  • 批准号:
    09660327
  • 负责人:
  • 金额:
    $ 2.05万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    1997
  • 资助国家:
    日本
  • 起止时间:
    1997 至 1998
  • 项目状态:
    已结题

项目摘要

It has been reported that doxorubicin, an anthracycline anticancer chemotherapeutic agent, produces anticholinergic effects in heart. In the present study, the anticholinergic effects of 5 different anticancer chemotherapeutic agents were compared with the effect of doxorubicin by mean of cellular electrophysiological method. The acetylcholine-operated potassium channel (KAch) current induced by carbachol was measured by patch clamp method in isolated guinea-pig atrial myocytes. Only 2 drugs, doxorubicin and mitoxantrone, inhibited the KACh current in a concentration dependent manner. Both drugs reversed neither adenosine-induced KAch current nor adenosine-induced action potential shortening. Moreover, doxorubicin did not affect the intracellular GTPgammaS-activated KACh current. From these data, it is concludes that doxorubicin and mitoxantrone interact with muscarinic M2 receptor in myocardium to produce their anticholinergic effects.. Functional studies using isolated left atria and ileal muscles were conducted to confirm the interaction of doxorubicin with M2 and M3 receptors pharmacologically. In left atria and ilea, doxorubicin shifted the concentration-response curves for the negative inotropic effect and the contracting effect of carbachol to a same extent in a parallel manner. Thus, doxorubicin did not discriminate between M_2 and M_3 receptors. Atrial preparations from chronic doxorubicin-treated rats exhibited decreases in developed tension and the negative inotropic response to carbachol. However, there was rio quantitative change in GTP binding protein, which was measured by SDS-PAGE and western blotting method, in membrane preparation of ventricular muscle from chronic doxorubicin-treated rats. These results indicate that doxorubicin and chemically related anticancer chemotherapeutic agents exert anticholinergic effects. The site of anticholinergic action of the drugs is on muscarinic receptor level, similar to atropine.
据报道,阿霉素是一种蒽环类抗癌化疗药物,对心脏产生抗胆碱能作用。本研究通过细胞电生理方法比较了5种不同抗癌化疗药物的抗胆碱能作用与阿霉素的作用。采用膜片钳法测量离体豚鼠心房肌细胞中卡巴胆碱诱导的乙酰胆碱钾通道(KAch)电流。只有阿霉素和米托蒽醌两种药物以浓度依赖性方式抑制 KACh 电流。这两种药物既不能逆转腺苷诱导的 KAch 电流,也不能逆转腺苷诱导的动作电位缩短。此外,阿霉素不影响细胞内GTPgammaS激活的KACh电流。从这些数据可以得出结论,阿霉素和米托蒽醌与心肌中的毒蕈碱M2受体相互作用,产生抗胆碱能作用。使用分离的左心房和回肠肌肉进行功能研究,以在药理学上证实阿霉素与M2和M3受体的相互作用。在左心房和回肠中,阿霉素以平行方式将负性肌力作用和卡巴胆碱收缩作用的浓度-反应曲线移动到相同程度。因此,阿霉素不区分M_2和M_3受体。长期接受阿霉素治疗的大鼠的心房制剂表现出张力减弱和对卡巴胆碱的负性肌力反应。然而,在慢性阿霉素处理的大鼠心室肌膜制剂中,通过 SDS-PAGE 和蛋白质印迹法测量,GTP 结合蛋白出现了 rio 定量变化。这些结果表明阿霉素和化学相关的抗癌化疗剂发挥抗胆碱能作用。该药物的抗胆碱能作用位点位于毒蕈碱受体水平,与阿托品相似。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
原 幸男: "モルモット心房筋細胞のムスカリン感受性カリウム電流におよぼすミトキサントロンの影響" 日本薬理学雑誌. 113. 8- (1999)
Yukio Hara:“米托蒽醌对豚鼠心房肌细胞毒蕈碱敏感性钾电流的影响”日本药理学杂志 113. 8- (1999)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
原 幸男: "モルモット心房筋細胞のムスカリン感受性カリウム電流におよぼすミトキサントロンの影響" 日本薬理学雑誌. 113・2. 8 (1999)
Yukio Hara:“米托蒽醌对豚鼠心房肌细胞毒蕈碱敏感性钾电流的影响”日本药理学杂志,113, 2. 8 (1999)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yukio Hara: "Anticholinergic effect of doxorubicin in isolated guinea pig heart." Japanese Journal of Pharmacology. 76 : (Suppl.I). 82 (1998)
Yukio Hara:“多柔比星对离体豚鼠心脏的抗胆碱能作用。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yukio Hara: "Anticholinergic effect of doxorubicin in isolated guinea pig heart" Japanese Journal of Pharmacology. 76・S-I. 82 (1998)
Yukio Hara:“多柔比星对离体豚鼠心脏的抗胆碱能作用”日本药理学杂志 76・S-I 82(1998)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yukio Hara: "Anticholinergic effect of doxorubicin in isolated guinea pig heart" Japanese Journal of Pharmacology. 76. 82- (1998)
Yukio Hara:“多柔比星对离体豚鼠心脏的抗胆碱能作用”日本药理学杂志。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HARA Yukio其他文献

HARA Yukio的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HARA Yukio', 18)}}的其他基金

Neural mechanisms of cardiotoxicity of novel cytotoxins produced by methicillin-resistant Staphylococcus aureus
耐甲氧西林金黄色葡萄球菌产生的新型细胞毒素心脏毒性的神经机制
  • 批准号:
    06672267
  • 财政年份:
    1994
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似海外基金

Functional Analysis of Girdin in Anticancer Drug-Resistant Pancreatic Cancer and Its Application to Novel Therapeutic Agents
Girdin在抗癌药物耐药性胰腺癌中的功能分析及其在新型治疗药物中的应用
  • 批准号:
    23K08138
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of tumor development mechanism by immune escape mechanism through metabolic reprogramming of anticancer drug-resistant cancer
通过抗癌药物耐药性癌症的代谢重编程的免疫逃逸机制阐明肿瘤发生机制
  • 批准号:
    23K18344
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Development of anticancer drug candidates from natural products target for pancreatic cancer cells
从天然产物中开发针对胰腺癌细胞的抗癌候选药物
  • 批准号:
    23K14377
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Challenge to refractory cervical cancer using a foci-specific anticancer drug production biosystem
使用病灶特异性抗癌药物生产生物系统挑战难治性宫颈癌
  • 批准号:
    23K08892
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development and Functional Evaluation of Cyclic Pyrrole-Imidazole Polyamides for Anticancer Drug Applications
用于抗癌药物应用的环状吡咯-咪唑聚酰胺的开发和功能评价
  • 批准号:
    22KJ1695
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Discovery of a novel anticancer drug targeting a WW domain of YAP protein
发现一种针对 YAP 蛋白 WW 结构域的新型抗癌药物
  • 批准号:
    23K04949
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Establishment of skin care standard for prevention of aggravation of skin disorders associated with anticancer drug treatment
制定皮肤护理标准,预防与抗癌药物治疗相关的皮肤疾病恶化
  • 批准号:
    23K09893
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Impact of anticancer drug administration to pregnant women on birth and infant outcomes using healthcare and medical big data analysis
使用医疗保健和医疗大数据分析抗癌药物对孕妇的出生和婴儿结局的影响
  • 批准号:
    23K14428
  • 财政年份:
    2023
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Biodegradable Polymer Nanodiscs as Novel Lipoprotein-Mimicking Nanocarriers for Anticancer Drug Delivery with High Stability and Long Circulation Time
可生物降解的聚合物纳米盘作为新型脂蛋白模拟纳米载体,用于高稳定性和长循环时间的抗癌药物输送
  • 批准号:
    2213969
  • 财政年份:
    2022
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Standard Grant
Development of pancreatic cancer treatment using fibrosis-inhibiting peptide and anticancer drug-encapsulating liposome
使用纤维化抑制肽和抗癌药物封装脂质体治疗胰腺癌的进展
  • 批准号:
    22K07971
  • 财政年份:
    2022
  • 资助金额:
    $ 2.05万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了